SINOVAC BIOTECH LTD's ticker is SVA and the CUSIP is P8696W104. A total of 37 filers reported holding SINOVAC BIOTECH LTD in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $1,000 | -90.0% | 187 | -88.4% | 0.00% | – |
| Q4 2016 | $10,000 | -98.4% | 1,611 | -98.5% | 0.00% | -100.0% |
| Q3 2016 | $644,000 | -61.7% | 109,198 | -61.5% | 0.00% | -50.0% |
| Q2 2016 | $1,681,000 | -7.2% | 283,505 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,812,000 | +4319.5% | 283,505 | +3396.2% | 0.00% | – |
| Q3 2015 | $41,000 | -4.7% | 8,109 | -1.1% | 0.00% | – |
| Q2 2015 | $43,000 | +19.4% | 8,198 | +12.8% | 0.00% | – |
| Q1 2015 | $36,000 | -41.0% | 7,270 | -37.5% | 0.00% | – |
| Q4 2014 | $61,000 | +90.6% | 11,624 | +74.6% | 0.00% | – |
| Q3 2014 | $32,000 | +14.3% | 6,656 | +33.5% | 0.00% | – |
| Q2 2014 | $28,000 | -75.2% | 4,985 | -68.3% | 0.00% | – |
| Q1 2014 | $113,000 | +145.7% | 15,715 | +109.1% | 0.00% | – |
| Q4 2013 | $46,000 | -73.3% | 7,517 | -73.9% | 0.00% | – |
| Q3 2013 | $172,000 | +132.4% | 28,791 | +51.1% | 0.00% | – |
| Q2 2013 | $74,000 | – | 19,052 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,718,735 | $340,500,000 | 6.32% |
| Vivo Capital, LLC | 5,900,000 | $38,173,000 | 4.21% |
| Neumann Advisory Hong Kong Ltd | 315,586 | $2,042 | 0.72% |
| Yorktown Management & Research Co Inc | 74,893 | $485,000 | 0.63% |
| Skandinaviska Enskilda Banken AB (publ) | 40,000 | $259,000 | 0.00% |
| Renaissance Technologies | 2,375,841 | $1,537,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 1,687 | $11,000 | 0.00% |
| NORTHERN TRUST CORP | 13,787 | $55,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 412 | $27,000 | 0.00% |